NASA awards Redwire $4 million for space drug development research
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- Wall St falls as Trump's Iran remarks weigh on markets
- Oil jumps around 5% to two-week high after Trump warns of more attacks on Iran
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
NASA Awards Redwire $4 Million In Additional Funding to Support Trailblazing Drug Development in Microgravity
March 11, 2026 7:00 AM EDTJACKSONVILLE, Fla.--(BUSINESS WIRE)-- Redwire Corporation (NYSE: RDW), a global leader in space and defense technology solutions, today announced that NASA has awarded the company an additional $4 million to support new drug development investigations on the International Space Station (ISS) using Redwires Pharmaceutical In-space Laboratory (PIL-BOX) technology. This additional funding expands an existing task order under a $25 million, five-year indefinite-delivery/indefinite-quantity contract through NASAs In Space Production Applications (InSPA) program.
The space and pharmaceutical industries are coming together in a way that will transform both fields,... More
